NeuroSense Therapeutics (NRSN) Total Current Liabilities (2020 - 2025)
NeuroSense Therapeutics (NRSN) posted Total Current Liabilities of $2.5 million for Q4 2025, up 14.21% sequentially from $2.2 million in Q2 2025, and up 26.31% YoY from $2.0 million in Q4 2024.
NeuroSense Therapeutics (NRSN) Total Current Liabilities (2020 - 2025) Analysis & Trends
NeuroSense Therapeutics has reported Total Current Liabilities for 6 years, with the latest figure at $2.5 million in Q4 2025.
- Quarterly Total Current Liabilities rose 26.31% year-over-year to $2.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.5 million (up 26.31% YoY) and the FY2025 annual result came in at $2.5 million, up 26.31% from the prior year.
- Total Current Liabilities rose to $2.5 million in Q4 2025 per NRSN's latest filing, from $2.2 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $3.0 billion in Q2 2023 and troughed at $597000.0 in Q4 2021.
- A 5-year average of $202.4 million and a median of $2.2 million in 2025 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Current Liabilities soared 408188.04% in 2023, then slumped 99.88% in 2024.
- Over 5 years, Total Current Liabilities stood at $597000.0 in 2021, then surged by 189.11% to $1.7 million in 2022, then jumped by 100.41% to $3.5 million in 2023, then slumped by 42.41% to $2.0 million in 2024, then climbed by 26.31% to $2.5 million in 2025.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $2.5 million, $2.2 million, and $2.0 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | NeuroSense Therapeutics | 9.68 Mn | 9.47 Mn | - | 2.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.52 Mn |
| Jun 30, 2025 | 2.20 Mn |
| Dec 31, 2024 | 1.99 Mn |
| Sep 30, 2024 | 3.78 Mn |
| Jun 30, 2024 | 3.51 Mn |
| Mar 31, 2024 | 4.54 Mn |
| Dec 31, 2023 | 3.46 Mn |
| Sep 30, 2023 | 2.81 Mn |
| Jun 30, 2023 | 3.01 Bn |
| Mar 31, 2023 | 1.79 Mn |
| Dec 31, 2022 | 1.73 Mn |
| Sep 30, 2022 | 811,000.00 |
| Jun 30, 2022 | 736,000.00 |
| Mar 31, 2022 | 1.23 Mn |
| Dec 31, 2021 | 597,000.00 |
| Dec 31, 2020 | 120,000.00 |